ML SA1

CAS No. 332382-54-4

ML SA1 ( Mucolipin synthetic agonist 1 )

Catalog No. M24271 CAS No. 332382-54-4

ML-SA1 is a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 42 In Stock
10MG 67 In Stock
25MG 139 In Stock
50MG 230 In Stock
100MG 346 In Stock
200MG 520 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ML SA1
  • Note
    Research use only, not for human use.
  • Brief Description
    ML-SA1 is a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity.
  • Description
    ML-SA1 is a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively[1].
  • Synonyms
    Mucolipin synthetic agonist 1
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    TRPML
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    332382-54-4
  • Formula Weight
    362.4
  • Molecular Formula
    C22H22N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:17 mg/mL (46.90 mM)
  • SMILES
    CC(CC1(C)C)c(cccc2)c2N1C(CN(C(c1c2cccc1)=O)C2=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Xia Z, et al. ML-SA1, a selective TRPML agonist, inhibits DENV2 and ZIKV by promoting lysosomal acidification and protease activity. Antiviral Res. 2020;182:104922.
molnova catalog
related products
  • TM6089

    TM6089 is a unique Prolyl Hydroxylase inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia.

  • CNP-AFU

    CNP-AFU is the substrate of alpha-L-fucosidase.

  • Dammarenediol II

    Dammarenediol II may have the ability to prevent diabetic microvascular complications, including diabetic retinopathy.